IL310269A - Bifunctional compounds for BTK degradation with enhanced IMID activity - Google Patents
Bifunctional compounds for BTK degradation with enhanced IMID activityInfo
- Publication number
- IL310269A IL310269A IL310269A IL31026924A IL310269A IL 310269 A IL310269 A IL 310269A IL 310269 A IL310269 A IL 310269A IL 31026924 A IL31026924 A IL 31026924A IL 310269 A IL310269 A IL 310269A
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- membered
- heterocycloalkyl
- compound
- independently selected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225401P | 2021-07-23 | 2021-07-23 | |
| PCT/US2022/038084 WO2023004163A1 (en) | 2021-07-23 | 2022-07-22 | Bifunctional compounds for degrading btk with enhanced imid activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310269A true IL310269A (en) | 2024-03-01 |
Family
ID=82898772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310269A IL310269A (en) | 2021-07-23 | 2022-07-22 | Bifunctional compounds for BTK degradation with enhanced IMID activity |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250017922A1 (https=) |
| EP (1) | EP4373493A1 (https=) |
| JP (1) | JP2024526984A (https=) |
| KR (1) | KR20240039001A (https=) |
| CN (1) | CN118019539A (https=) |
| AU (1) | AU2022313210A1 (https=) |
| CA (1) | CA3226590A1 (https=) |
| IL (1) | IL310269A (https=) |
| MX (1) | MX2024000947A (https=) |
| WO (1) | WO2023004163A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| CN115557933B (zh) * | 2021-07-01 | 2024-08-16 | 杭州和正医药有限公司 | 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用 |
| AU2022379494A1 (en) * | 2021-10-26 | 2024-05-30 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| CN120202200A (zh) * | 2023-06-01 | 2025-06-24 | 标新生物医药科技(上海)有限公司 | 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用 |
| CN121335894A (zh) * | 2024-02-04 | 2026-01-13 | 上海超阳药业有限公司 | 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
-
2022
- 2022-07-22 WO PCT/US2022/038084 patent/WO2023004163A1/en not_active Ceased
- 2022-07-22 AU AU2022313210A patent/AU2022313210A1/en active Pending
- 2022-07-22 US US18/290,920 patent/US20250017922A1/en active Pending
- 2022-07-22 KR KR1020247006052A patent/KR20240039001A/ko active Pending
- 2022-07-22 IL IL310269A patent/IL310269A/en unknown
- 2022-07-22 CN CN202280064042.4A patent/CN118019539A/zh active Pending
- 2022-07-22 MX MX2024000947A patent/MX2024000947A/es unknown
- 2022-07-22 JP JP2024504199A patent/JP2024526984A/ja active Pending
- 2022-07-22 CA CA3226590A patent/CA3226590A1/en active Pending
- 2022-07-22 EP EP22754662.9A patent/EP4373493A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3226590A1 (en) | 2023-01-26 |
| CN118019539A (zh) | 2024-05-10 |
| KR20240039001A (ko) | 2024-03-26 |
| AU2022313210A1 (en) | 2024-02-08 |
| EP4373493A1 (en) | 2024-05-29 |
| JP2024526984A (ja) | 2024-07-19 |
| WO2023004163A1 (en) | 2023-01-26 |
| MX2024000947A (es) | 2024-04-12 |
| US20250017922A1 (en) | 2025-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12600732B2 (en) | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | |
| US20250017922A1 (en) | Bifunctional compounds for degrading btk with enhanced imid activity | |
| US12583862B2 (en) | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | |
| US12582722B2 (en) | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | |
| US20240336595A1 (en) | Bifunctional compounds for degrading btk with diminished imid activity | |
| EP4055019A1 (en) | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway | |
| US8304423B2 (en) | Modulators of muscarinic receptors | |
| US7786107B2 (en) | Modulators of muscarinic receptors | |
| BR122023025072A2 (pt) | Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma |